NASDAQ OMX

LifeSci Advisors Announces 14th Board Appointment Through Its Board Placement Initiative

Dela

NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- LifeSci Advisors, an investor relations and corporate communications firm focused on the life sciences sector, today announces the 14th appointment of a female executive to a life sciences company board as part of its Board Placement Initiative (BPI), the second appointment this year for the Company. Launched in 2016, LifeSci Advisors' BPI aims to connect female executives in the life sciences industry with companies seeking board candidates. As more companies look to fill their board with LifeSci's assistance and as more qualified candidates are referred to LifeSci, the BPI network expands and the amount of connections between companies and candidates increase.

LifeSci is pleased to share that Caroline M. Loewy has been appointed to the Board of Directors for Aptose Biosciences Inc., a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer.

"Aptose is an exciting company in the anti-cancer therapy space, and I am excited to join their board," said Caroline Loewy. "I look forward to collaborating with the Aptose team as the Company continues to develop novel oncology therapies intended to treat life-threatening cancers."

Caroline Loewy has over two decades of experience working within the life sciences sector, promoting and analysing biotechnology product development and growth as well as advising biopharmaceutical companies. In addition to offering counseling, she has served on the executive team of Achieve Life Sciences, Inc. (which she co-founded), Tobira Therapeutics, Inc., Corcept Therapeutics Inc., and Poniard Pharmaceuticals, Inc. Moreover, she has accumulated several years of managerial and research experience at Morgan Stanley Inc., Prudential Securities, and Bank of America Corporation. Caroline is a founding board member of the KCNQ2 Cure Alliance Foundation and a founding board member of the Global Genes Project. She sits on the Board of Directors of CymaBay Therapeutics Inc. and is a member of the National Advisory Council of the Translational Genomics Research Institute (TGen) Center for Rare Childhood Disorders. Caroline holds a B.A. degree from the University of California, Berkeley, and an M.B.A./M.S. degree from Carnegie Mellon University.

"The Aptose team welcomes Caroline to our board with enthusiasm. We are delighted to receive her guidance during this pivotal year as we continue to develop our targeted drugs for life-threatening hematologic malignancies at Aptose," said William G. Rice,  Ph.D., Chairman, President and Chief Executive Officer. "Caroline has extensive background experience advising and serving on executive teams of publically traded biotechnology companies. Her appointment to our board would not have been possible without LifeSci Advisors, whom we'd like to thank for introducing us to Caroline, a talented and skilled individual with diverse and learned insight."

"It gives me great pleasure to connect Caroline with Aptose Biosciences. Her breadth of knowledge stemming from years as a board member, founder, executive leader and analyst in the biotech and financial services industries will be an enormous resource to the Aptose team," said Michael Rice, President and Co-Founder, LifeSci Advisors. "Each board placement garners traction as we hope to grow our initiative by expanding our network and placing more exceptional candidates on boards. Our colleagues, the companies in our network, and the candidates referred have all been a tremendous support to BPI. We'd like to thank each for their participation and trust in this cause."

LifeSci Advisors' Board Placement Initiative (BPI) was launched to encourage companies in the life sciences industry to diversify and strengthen their company boards. LifeSci meets with a company's management team or Board regarding the skills and expertise they are seeking in a candidate. After the LifeSci team properly vets board candidates, LifeSci will then make introductions between companies and eligible board candidates. Currently, BPI has helped place 14 women on corporate boards with the intention of continuing this success. Using a proprietary network comprised of board-ready women that the company has built over the last couple years, LifeSci Advisors hopes that BPI can become a valuable platform where both female executives and life sciences companies are able to network and to grow.

BPI is accepting resumes from interested candidates and referrals on an ongoing basis. To find out how you can use the BPI network for your next board candidate search, visit www.lifesciadvisors.com/board-diversity-initiatives. Inquiries, resume submissions, and open board seat referrals can be sent to boarddiversity@lifesciadvisors.com.

LifeSci Advisors, LLC (www.lifesciadvisors.com) is the largest investor relations consultancy in the life sciences industry, founded to provide companies with a multi-faceted approach to investor communications and outreach. With a global focus and reach, the firm provides the highest quality service for its clients through its deep sector specialization. LifeSci's team of MDs and PhDs enables the firm to better understand clients' R&D, regulatory and commercial strategies, and its team of financial services, investor relations and public relations specialists helps clients effectively communicate to the marketplace. This combination of life sciences, financial services, and investor relations competencies allows LifeSci Advisors to provide an invaluable and unique service offering to clients.
 
LifeSci Partners 
(www.lifescipartners.com) is the leading provider of consulting services in the areas of investor relations, public relations, corporate communications and capital markets advisory. Combining deep domain expertise in the life sciences with decades of experience in capital markets and public relations, LifeSci Partners delivers unparalleled services to life sciences companies globally.

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit www.aptose.com.

For further information, please contact:

Morgen Alden                                                                                   
LifeSci Advisors, LLC
212-915-2581
morgen@lifesciadvisors.com
www.lifesciadvisors.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LifeSci Advisors, LLC via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

BK Ultrasound, Powered by Analogic, Launches bkSpecto Ultrasound System for Urology at the 2018 American Urological Association Annual Meeting18.5.2018 23:23Pressmeddelande

PEABODY, Mass., May 18, 2018 (GLOBE NEWSWIRE) -- Analogic Corporation (Nasdaq:ALOG), enabling the world's medical imaging and aviation security technology, today announced that it will launch the bkSpecto(TM) ultrasound system at the 113th AUA (American Urological Association) Annual Meeting, May 18-21, in San Francisco. bkSpecto-taken from the Latin word Specto, meaning 'I see'-is BK Ultrasound's all-new ultrasound platform designed for clinical practices. bkSpecto combines BK's advanced auto-optimization algorithms with faster processing to render exceptional anatomical imaging detail with minimal manual adjustment by the user. The system has a unique glass touch-based interface using BK's Tru-Sense(TM) technology to provide 'sightless navigation.' The interface enables tactile feedback with or without gloves, providing an intuitive, self-guided user experience. The interface is also customizable, enabling personalized and faster user workflows. The small footprint of bkSpecto makes

BIMobject AB: BIMobject publicerar årsredovisning för 201718.5.2018 17:25Pressmeddelande

BIMobject, som digitaliserar byggbranschen bland annat via molnbaserade plattformar, har idag publicerat årsredovisningen för 2017 på bolagets hemsida. "Det är med stolthet vi offentliggör årsredovisningen för året 2017 - ett år som för oss inte kan beskrivas annat än som 'explosivt'. Det är fantastiskt roligt att se hur vi fortsätter att effektivisera branscher som äntligen börjar se nyttan och digitaliseringens fulla potential. Att vi sedan har fyra starka trender som ger oss vind i seglet gör framtiden ännu mer lockande. Nu är vi i ett spännande 2018 där vi bland annat ser fram emot att passera milstolpen 1 miljon användare", säger Stefan Larsson, VD på BIMobject. Årsredovisningen finns tillgänglig för nedladdning på: http://info.bimobject.com/bimobject_data/documents/Documents/2017/bimobject-%C3%A5rsredovisning-2017.pdf För mer information, vänligen kontakta: Stefan Hansson - CFO Tel: +46 40 - 685 29 00 E-mail: press@bimobject.com ______________________________________________ Denn

Brookfield Asset Management Announces Renewal of Normal Course Issuer Bid18.5.2018 12:55Pressmeddelande

TORONTO, May 18, 2018 (GLOBE NEWSWIRE) -- Brookfield Asset Management Inc. (NYSE:BAM) (TSX:BAM.A) (EURONEXT:BAMA) ("Brookfield") today announced it has received approval from the Toronto Stock Exchange ("TSX") for the renewal of its normal course issuer bid to purchase up to 82,315,909 Class A Limited Voting Shares ("Class A Shares"), representing 10% of the public float of Brookfield's outstanding Class A Shares. Purchases under the bid will be made through the facilities of the TSX, the New York Stock Exchange ("NYSE") and any alternative Canadian trading system. The period of the normal course issuer bid will extend from May 24, 2018 to May 23, 2019, or an earlier date should Brookfield complete its purchases. Brookfield will pay the market price at the time of acquisition for any Class A Shares purchased. As at May 1, 2018, the number of Class A Shares issued and outstanding totalled 991,857,711, of which 823,159,095 shares represented the public float. In accordance with the rules

Mandalay Resources Corporation går ut med resultaten från årsstämman samt registreringen av ESTMA-rapporten och utnämningen av styrelseledamot17.5.2018 22:00Pressmeddelande

TORONTO den 17 maj 2018 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" eller "Bolaget") (TSX:MND) har nöjet att meddela resultatet från årsstämman ("årsstämman") som hölls i dag i Toronto, Ontario. Alla resolutioner som presenterades vid årsstämman godkändes av aktieägarna och röstningen som skedde genom fullmakt motsvarade 79,15 % av de totalt utestående aktierna vid tidsfristen för fullmakter den 14 maj 2018. Val av styrelseledamöter Som meddelat den 14 maj 2018, har Mark Sander avgått som Bolagets President och Chief Executive Officer och drog också tillbaka sin kandidatur för återval till styrelsen. Som resultat fastställdes antalet styrelseledamöter till fem medlemmar och samtliga av de fem nominerade som fanns i bolagsledningens informationsutskick från den 13 april 2018 ("informationsutskicket"), undantaget Mark Sander, valdes om till Bolagets styrelse. Abraham Jonker förblir ledande oberoende styrelseledamot och Bradford Mills fortsätter som styrelseordförande.

Skybox Security and Exclusive Networks Announce New Partnership for Middle East Distribution of the Skybox Security Suite17.5.2018 18:41Pressmeddelande

The cybersecurity management platform ensures networks remain secure and compliant as organisations migrate to cloud and merge networks SAN JOSE, Calif., May 17, 2018 (GLOBE NEWSWIRE) -- Skybox(TM) Security, a global leader in cybersecurity management, announced today a new partnership with Exclusive Networks for distribution of Skybox solutions in the Middle East, including the Gulf Cooperation Council (GCC) region and Egypt. Exclusive Networks will deploy and service the Skybox(TM) Security Suite, a broad security management platform that provides comprehensive attack surface visibility and enables unified vulnerability management and firewall/security policy management across an organization's entire network, including in physical, multi-cloud and OT environments. "Driven by government outlays (with oil, gas and defence industries leading the charge), Middle East organisations are looking for trusted security advisors who can navigate digital transformations and reduce risks - espec

Dermatological Symposium Tackles the Effects of Pollution on Skin17.5.2018 16:03Pressmeddelande

Researchers Present Compelling Evidence Showing the Effects of Pollution on Skin Health at Symposium Sponsored by Mary Kay Inc. DALLAS, May 17, 2018 (GLOBE NEWSWIRE) -- Mary Kay Inc. announced four keynote speakers for its symposium to be held during the prestigious International Investigative Dermatology (IID) Meeting on May 16 to 19, 2018 in Orlando, Florida. The IID meeting occurs once every 5 years, and brings together scientists from across the globe, highlighting the latest in cutting edge science in dermatology. The Mary Kay sponsored Symposium features four global experts including Dr. Liang Liu, Assistant Professor of Dermatology, Columbia University; Dr. Max Costa, Professor and Chairman of the department of Environmental Medicine, New York University School of Medicine; Dr. Jean Krutmann, Chair of Environmental Medicine at the Medical Faculty of Heinrich Heine University Düsseldorf and Director of the Leibniz Research Institute of Environmental Medicine in Dusseldorf, German

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum